What other conditions can cause a left ventricular wall thickness of 2 cm besides hypertrophic obstructive cardiomyopathy?

Differential Diagnosis of 2 cm LV Wall Thickness

A 2 cm (20 mm) left ventricular wall thickness has a broad differential diagnosis beyond hypertrophic cardiomyopathy, most importantly including infiltrative diseases (cardiac amyloidosis, Fabry disease), metabolic/storage disorders (PRKAG2, Danon disease, mitochondrial disease), hypertensive heart disease, and athlete's heart—with the specific pattern of hypertrophy, clinical context, and additional testing being critical to distinguish these entities.

Primary Differential Considerations

Infiltrative Cardiomyopathies

The most critical mimics to exclude with 20 mm wall thickness are infiltrative diseases 1, 2:

• Cardiac amyloidosis (transthyretin or light chain): Look for concentric LVH, biatrial enlargement, "apical sparing" strain pattern on echo, diffuse subendocardial late gadolinium enhancement on CMR, and markedly elevated native T1/ECV values 3
• Fabry disease: Consider in younger patients, check for extracardiac manifestations (angiokeratomas, renal disease, neuropathy), typically shows inferolateral wall involvement 4, 5
• Cardiac sarcoidosis: Look for patchy LGE patterns, conduction abnormalities, and extracardiac sarcoid involvement

Metabolic/Storage Disorders

Particularly important in younger patients 4:

• PRKAG2 mutations: AMP-kinase gene mutations causing glycogen storage
• Danon disease (LAMP2 mutations): X-linked, associated with skeletal myopathy and intellectual disability
• Mitochondrial cardiomyopathy: Consider with multisystem involvement
• Pompe disease: Glycogen storage disorder

Secondary Causes of LVH

Hypertensive heart disease is the most common diagnostic challenge, especially when wall thickness is 13-15 mm, but can occasionally reach 20 mm 5:

• Typically shows concentric pattern rather than asymmetric septal hypertrophy
• LV cavity may be normal or enlarged (not small/obliterated)
• Absence of LVOT obstruction or SAM
• History of long-standing hypertension
• Normal diastolic function relative to degree of hypertrophy

Athlete's heart 5, 4, 2:

• Usually wall thickness <15 mm, rarely reaches 20 mm
• LV cavity enlargement (>54 mm) favors physiologic adaptation
• Normal diastolic function
• Regression with 3-6 months deconditioning confirms diagnosis
• Symmetric distribution of hypertrophy

Less Common Causes

Aortic stenosis: Produces pressure-overload hypertrophy, but valve pathology is evident 6

Drug-induced LVH 7:

• Anabolic steroids
• Tacrolimus
• Hydroxychloroquine
• (Rarely produce wall thickness ≥15 mm)

Diagnostic Algorithm for 20 mm Wall Thickness

Step 1: Pattern Recognition on Imaging

• Asymmetric septal hypertrophy + LVOT obstruction + SAM → HCM likely
• Concentric LVH + biatrial enlargement + apical sparing strain → Amyloidosis likely 3
• Inferolateral predominance in younger patient → Consider Fabry disease
• Concentric LVH + long-standing hypertension history → Hypertensive heart disease possible

Step 2: Clinical Context Assessment

• Family history of HCM or sudden cardiac death → Genetic HCM more likely 5
• Extracardiac symptoms (neuropathy, renal disease, skin lesions) → Systemic disease (Fabry, amyloidosis, sarcoid) 1, 2
• Age of onset: Younger patients favor genetic causes; elderly favor amyloidosis or hypertensive disease
• Elite athletic training history → Consider athlete's heart, but 20 mm is unusual

Step 3: Advanced Tissue Characterization

Cardiac MRI is essential 6, 3:

• Patchy mid-wall/junctional LGE → HCM
• Diffuse subendocardial/transmural LGE + markedly elevated T1/ECV → Amyloidosis
• Inferolateral LGE + low T1 values → Fabry disease (lipid accumulation)

Step 4: Specialized Testing

• Genetic testing: For sarcomeric mutations if HCM suspected; consider PRKAG2, LAMP2 if phenotype atypical 4, 1
• Serum/urine protein electrophoresis + free light chains: If amyloidosis suspected
• Alpha-galactosidase A levels: If Fabry disease suspected
• Technetium-pyrophosphate scan: Grade 2-3 uptake confirms ATTR amyloidosis 8
• Endomyocardial biopsy: Reserved for diagnostic uncertainty after non-invasive testing 8

Critical Pitfalls to Avoid

1. Do not assume all LVH ≥15 mm is HCM: The 2020 AHA/ACC guideline explicitly states that systemic disorders producing similar wall thickness should NOT be labeled as HCM 1, 2

2. Do not miss amyloidosis in elderly patients: Wild-type ATTR amyloidosis is increasingly recognized and can present identically to HCM with severe hypertrophy 9

3. Do not rely solely on wall thickness measurements: One-third of HCM patients have segmental hypertrophy with normal LV mass 4

4. In patients with hypertension history and LVH: Marked wall thickness ≥25 mm and/or LVOT obstruction with SAM strongly favors coexistent HCM over pure hypertensive disease 5

5. Consider sex-specific differences: Women have lower baseline wall thickness; indexing to body surface area or height^2.7 may reveal more severe disease than absolute measurements suggest 9

The key distinction is that HCM is defined as unexplained LVH in the absence of another disease capable of producing that magnitude of hypertrophy 4, 1, 4. Therefore, systematic exclusion of infiltrative, metabolic, and secondary causes is mandatory before confirming isolated HCM.